SCHEMBL4598174

SCHEMBL4598174

Cc1ccc(S(=O)(=O)NC(Cc2ccc(Oc3ccc(C(=O)NO)c(C)c3)cc2)C(=O)N(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.48
MMP13 P45452 5/20 0.47
MMP9 P14780 6/20 0.43
MMP1 P03956 3/20 0.42
ITGB3 P05106 1/20 0.42
ITGA2B P08514 1/20 0.42
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 1/20 0.41
F2 P00734 5/20 0.41
CTSL P07711 1/20 0.41
PRSS1 P07477 1/20 0.40
CYP1A2 P05177 1/20 0.39
MMP2 P08253 2/20 0.39
POLB P06746 1/20 0.39
MMP3 P08254 1/20 0.39
MMP7 P09237 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4597749 0.90 TDP1 (0.54) TDP1MMP13MMP9MMP1ITGB3
SCHEMBL5123529 0.86 MMP13 (0.51) TDP1MMP13MMP9MMP1ITGB3
SCHEMBL4598594 0.86 TDP1 (0.49) TDP1MMP13MMP9ITGB3ITGA2B
SCHEMBL4597834 0.85 MMP13 (0.51) TDP1MMP13MMP9MMP1ITGB3
SCHEMBL4597080 0.82 MMP13 (0.49) TDP1MMP13MMP9MMP1ITGB3
SCHEMBL14045372 0.82 MMP13 (0.49) TDP1MMP13MMP9MMP1ITGB3
SCHEMBL14045371 0.81 NPSR1 (0.53) TDP1MMP13MMP9ITGB3ITGA2B
SCHEMBL4608941 0.81 NPSR1 (0.53) TDP1MMP13MMP9ITGB3ITGA2B
SCHEMBL4597815 0.81 TDP1 (0.57) TDP1MMP13MMP9MMP1F2
SCHEMBL4609773 0.79 TDP1 (0.48) TDP1MMP13MMP9ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200521-A1 Novel hydroxamic acid containing amino acid derivatives BEXEL PHARMACEUTICALS. INC. 2008-08-21 US claimed
EP-1906731-A2 NOVEL HYDROXAMIC ACID-CONTAINING AMINO ACID DERIVATIVES Bexel Pharmaceuticals Inc (US) 2008-04-09 EP claimed
WO-2007005603-A2 NOVEL HYDROXAMIC ACID-CONTAINING AMINO ACID DERIVATIVES BEXEL PHARMACEUTICALS, INC. (US) 2007-01-11 WO claimed
US-20070004776-A1 Novel hydroxamic acid-containing amino acid derivatives BEXEL PHARMACEUTICALS, INC. 2007-01-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200521-A1 Novel hydroxamic acid containing amino acid derivatives HGFAC, HCAR2, BCAT1 TDP1 4051/4885MMP13 534/4885MMP9 1292/4885
US-20070004776-A1 Novel hydroxamic acid-containing amino acid derivatives HGFAC, HCAR2, BCAT1 TDP1 3873/4885MMP13 639/4885MMP9 1385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.